MX2020007722A - Inhibidores de endonucleasa cap-dependientes. - Google Patents

Inhibidores de endonucleasa cap-dependientes.

Info

Publication number
MX2020007722A
MX2020007722A MX2020007722A MX2020007722A MX2020007722A MX 2020007722 A MX2020007722 A MX 2020007722A MX 2020007722 A MX2020007722 A MX 2020007722A MX 2020007722 A MX2020007722 A MX 2020007722A MX 2020007722 A MX2020007722 A MX 2020007722A
Authority
MX
Mexico
Prior art keywords
sub
cap
carbocyclyl
heterocyclyl
metabolite
Prior art date
Application number
MX2020007722A
Other languages
English (en)
Inventor
Ming - Chu Hsu
Chu - Chung LIN
Hung - Chuan Chen
Chiayn Chiang
Chi - Feng YEN
Original Assignee
Taigen Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taigen Biotechnology Co Ltd filed Critical Taigen Biotechnology Co Ltd
Publication of MX2020007722A publication Critical patent/MX2020007722A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un compuesto de la Fórmula (I) a continuación, o una sal, metabolito o profármaco farmacéuticamente aceptable del mismo; en donde la Fórmula (I): A1 es CR4 o N; A2 es CR5'R6' o NR7'; A3 es CR5'R6' o NR7'; cada uno de R1, R2, R2', R3, R3', R4, R5, R5', R6, R6 ', R7, y R7 ', independientemente, es hidrógeno, deuterio, halógeno, ciano, hidroxilo, carboxilo, amino, formilo, nitro, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alqueniloxi C2-6, alquilcarbonilo C1-6, alquiloxicarbonilo C1-6, alquilamina C1-6, carbociclilo C3-20, o heterociclilo C3- 20; o R5 y R6, R5' y R6', o R5 y R5', junto con el átomo adyacente al que están unidos cada uno, forman carbociclilo C3-10 o heterociclilo C3-10. Se proporcionan además un método para usar el compuesto descrito anteriormente, o la sal, metabolito o profármaco farmacéuticamente aceptable del mismo, para tratar la influenza y una composición farmacéutica que lo contiene.
MX2020007722A 2018-01-22 2019-01-22 Inhibidores de endonucleasa cap-dependientes. MX2020007722A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862620065P 2018-01-22 2018-01-22
PCT/US2019/014461 WO2019144089A1 (en) 2018-01-22 2019-01-22 Cap-dependent endonuclease inhibitors

Publications (1)

Publication Number Publication Date
MX2020007722A true MX2020007722A (es) 2020-09-09

Family

ID=67299629

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007722A MX2020007722A (es) 2018-01-22 2019-01-22 Inhibidores de endonucleasa cap-dependientes.

Country Status (22)

Country Link
US (1) US10596171B2 (es)
EP (1) EP3743424A4 (es)
JP (1) JP6994121B2 (es)
KR (1) KR102432975B1 (es)
CN (1) CN110300753B (es)
AU (1) AU2019209426B2 (es)
BR (1) BR112020014810A2 (es)
CA (1) CA3078391C (es)
CL (1) CL2020001919A1 (es)
CO (1) CO2020006411A2 (es)
EA (1) EA202090658A1 (es)
IL (1) IL274199B (es)
JO (1) JOP20200159A1 (es)
MX (1) MX2020007722A (es)
MY (1) MY197875A (es)
NZ (1) NZ763248A (es)
PE (1) PE20211240A1 (es)
PH (1) PH12020550921A1 (es)
SG (1) SG11202003014VA (es)
TW (1) TWI714951B (es)
WO (1) WO2019144089A1 (es)
ZA (1) ZA202002037B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020015669A1 (zh) * 2018-07-17 2020-01-23 南京明德新药研发有限公司 抗流感病毒三并环衍生物
CN112521386B (zh) * 2019-09-19 2023-05-26 周雨恬 具有抗病毒作用的多环吡啶酮化合物及其药物组合和用途
CN112574170A (zh) * 2019-09-29 2021-03-30 江西东邦药业有限公司 一种二苯并七元环衍生物及其制备方法和应用
CN112920202A (zh) * 2019-12-05 2021-06-08 北京凯因科技股份有限公司 一种帽依赖性蛋白酶抑制剂
CN113620948B (zh) * 2020-05-06 2022-11-25 太景医药研发(北京)有限公司 帽依赖性核酸内切酶抑制剂
TWI796701B (zh) * 2020-05-28 2023-03-21 太景生物科技股份有限公司 用於製備雜環化合物的中間體立體選擇性合成
CN113603689B (zh) * 2020-09-08 2023-07-21 石家庄迪斯凯威医药科技有限公司 多环吡啶酮化合物及其药物组合物和用途
CN113683613B (zh) * 2020-09-08 2023-06-09 知和(山东)大药厂有限公司 一种多环吡啶肟基化合物及其药物组合物和用途
CA3203543A1 (en) 2020-12-30 2022-07-07 Rhythm Mehra Additively manufactured cable gland
US20240025921A1 (en) * 2021-01-08 2024-01-25 Phaeno Therapeutics Co., Ltd. Pyridone multiple-membered ring derivatives and use thereof
WO2023072292A1 (zh) * 2021-11-01 2023-05-04 南京知和医药科技有限公司 一种高效抗病毒化合物及其用途
TW202408525A (zh) * 2022-06-27 2024-03-01 太景生物科技股份有限公司 包含帽依賴性核酸內切酶抑制劑的藥物組合物
CN116284048B (zh) * 2023-05-18 2023-08-15 长沙晶易医药科技股份有限公司 一种化合物及其制备方法、药物组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2444400T3 (en) 2009-06-15 2018-06-18 Shionogi & Co SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE
PT2620436T (pt) * 2010-09-24 2018-09-28 Shionogi & Co Profármaco de derivado de carbamoilo piridona policíclica substituída
PE20180194A1 (es) * 2015-04-28 2018-01-26 Shionogi & Co Derivados de piridona policiclica sustituida y profarmaco de los mismos
US9988390B2 (en) 2015-10-30 2018-06-05 F. Hoffmann-La Roche Ag Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6806413B2 (ja) * 2016-02-03 2021-01-06 塩野義製薬株式会社 多環性ピリドン誘導体およびそのプロドラッグ

Also Published As

Publication number Publication date
CO2020006411A2 (es) 2020-06-09
PH12020550921A1 (en) 2021-05-31
CA3078391C (en) 2022-08-16
PE20211240A1 (es) 2021-07-09
TW201938166A (zh) 2019-10-01
SG11202003014VA (en) 2020-04-29
JOP20200159A1 (ar) 2022-10-30
IL274199B (en) 2021-07-29
AU2019209426B2 (en) 2020-11-19
EP3743424A1 (en) 2020-12-02
JP2021512146A (ja) 2021-05-13
AU2019209426A1 (en) 2020-04-23
ZA202002037B (en) 2021-08-25
CA3078391A1 (en) 2019-07-25
WO2019144089A1 (en) 2019-07-25
MY197875A (en) 2023-07-21
CN110300753A (zh) 2019-10-01
KR20200086385A (ko) 2020-07-16
BR112020014810A2 (pt) 2020-12-08
KR102432975B1 (ko) 2022-08-16
JP6994121B2 (ja) 2022-01-14
EA202090658A1 (ru) 2020-10-12
TWI714951B (zh) 2021-01-01
NZ763248A (en) 2023-06-30
US10596171B2 (en) 2020-03-24
CN110300753B (zh) 2022-01-04
EP3743424A4 (en) 2021-10-06
US20190224198A1 (en) 2019-07-25
CL2020001919A1 (es) 2020-10-09
IL274199A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
MX2020007722A (es) Inhibidores de endonucleasa cap-dependientes.
MX2022003401A (es) Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo.
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2015008971A (es) Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor.
PH12018500777A1 (en) Farnesoid x receptor modulators
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
JO3811B1 (ar) مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
NZ708909A (en) Substituted reverse pyrimidine bmi-1 inhibitors
MX342104B (es) Derivados de cicloalquenil arilo para inhibidor de cetp.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
GEP201606507B (en) Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
CY1116391T1 (el) Αιθινυλο παραγωγα ως θετικοι αλλοστερικοι ρυθμιστες του mglur5
FI20115234A0 (fi) Uusia pyridatsinoni- ja pyridoniyhdisteitä
MX2022013273A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso.
ZA202206266B (en) Pd-l1 antagonist compound
EA202091293A1 (ru) Производные пиридинона и их применение в качестве селективных ингибиторов alk-2
MX2018015990A (es) Compuestos terapeuticos.
WO2016063301A3 (en) Aromatic derivatives as anti-malarial
MX2022007634A (es) Inhibidores de egfr.